Fox NewsNovartis (NVS) Receives FDA Approval of Odomzo as laBCC TreatmentStreetInsider.comNovartis (NYSE: NVS) announced the US Food and Drug Administration (FDA) has approved Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred ...FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell ...MarketWatchFDA approves Novartis's advanced skin cancer drugYahoo NewsFDA Approves Sonidegib for Basal Cell CarcinomaOncLiveMilitary Technologiesall 10 news articles »
Novartis (NVS) Receives FDA Approval of Odomzo as laBCC Treatment
Rating: 4.5
Diposkan Oleh: Unknown
